| Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It. | 06/26 10:06 | fool.com |
| Will Elevidys Approval Make Sarepta Stock An Acquisition Target? | 06/25 09:00 | forbes.com |
| Sarepta Therapeutics (SRPT) Soars 30.1%: Is Further Upside Left in the Stock? | 06/24 04:50 | zacks.com |
| Sarepta Therapeutics: Pushing The Edge And Creating The Horizon | 06/22 06:47 | seekingalpha.com |
| Sarepta CEO on what's next after expanded muscular dystrophy drug approval | 06/21 19:05 | youtube.com |
| TD Cowen's Ritu Bara talks Sarepta stock skyrocketing on FDA gene therapy approval | 06/21 17:45 | youtube.com |
| Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty | 06/21 13:52 | benzinga.com |
| Wall Street Beats to Host Conference Call with Sarepta CEO on Ground-Breaking Expanded Label Approval | 06/21 13:21 | businesswire.com |
| Sarepta Stock Surges On FDA News; Industrial Stock In Buy Zone | 06/21 12:29 | investors.com |
| FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label | 06/21 12:25 | zacks.com |